BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, June 19, 2026
Home » Topics » Disease categories and therapies » Substance use and poisoning

Substance use and poisoning
Substance use and poisoning RSS Feed RSS

3D illustration of a nerve cell
Neurology/Psychiatric

Novel dual opioid analgesic with improved safety profile disclosed

Aug. 25, 2023
Mu opioid receptors (MOR) agonists exert strong anti-nociceptive activity but their ability to cause tolerance and physical dependence are serious issues of concern and limit their use. The activation of another branch of opioid receptors discovered lately, the opioid-related nociceptin receptor 1 (OPRL1) has recently shown the ability to enhance MOR agonist-induced analgesia while limiting tolerance and side effects.
Read More
Illustration highlighting the brain's reward circuit.
Substance Use & Poisoning

First-in-class RXFP3 negative allosteric modulator RLX-33 prevents alcohol relapse in rats

Aug. 24, 2023
New treatment options are needed for the prevention of relapse to alcohol use, the major problem in the treatment of alcohol dependence in humans. The neuropeptide relaxin-3/RXFP3 plays a relevant role in the motivation for the reward process and is considered a possible therapeutic target in addictive behaviors.
Read More
Neurology/Psychiatric

Gene therapy shows early promise for treating severe alcohol addiction

Aug. 18, 2023
By Helen Albert
Research in rhesus monkeys has shown a gene therapy that enhanced activity in dopamine producing neurons in the brain was effective at stopping excessive alcohol consumption in previously addicted animals.
Read More
Substance Use & Poisoning

AAV2-hGDNF revealed as a novel strategy for substance use disorders

Aug. 17, 2023
Alcohol use disorder (AUD) refers to a medical condition, considered a brain disorder, where individuals are unable to stop drinking alcohol...
Read More
Illustration of head composed of alcoholic beverage glasses
Substance Use & Poisoning

NIH grant to support early development of Amygdala Neurosciences’ ALDH2 inhibitor for AUD

Aug. 2, 2023
Amygdala Neurosciences Inc. has been awarded a $2.0 million NIH grant to support IND-enabling and early-stage development of its selective, reversible, orally bioavailable aldehyde dehydrogenase 2 (ALDH2) inhibitor ANS-858 to treat alcohol use disorder (AUD).
Read More

US FDA’s draft guidance for opioid use disorder devices greets tepid industry interest

July 27, 2023
By Mark McCarty
The U.S. FDA has issued a draft guidance for devices intended to address opioid use disorder (OUD), a problem with a massive public health footprint that has defied the efforts of public health programs. The draft guidance highlights some of the difficulties in executing pivotal studies for these devices, but the FDA’s July 27 press omits any mention of a 2018 innovation challenge for this category of devices, a programmatic effort that seems to have yielded little in the way of tangible results.
Read More
Various pills and powders in small plastic ziplock bags
Substance Use & Poisoning

Cessation receives IND clearance for first-in-human study of CSX-1004 for prevention of fentanyl overdose

July 27, 2023
Cessation Therapeutics Inc. has obtained IND clearance from the FDA to initiate a first-in-human trial of CSX-1004 for the prevention of fentanyl overdose. The trial in healthy volunteers is expected to begin next month.
Read More
Drug research illustration
Substance Use & Poisoning

ADX-106772 reduces oxycodone taking and seeking in rats

July 25, 2023
Researchers from Addex Therapeutics Ltd. have published preclinical data for the novel positive allosteric modulator of the metabotropic glutamate mGlu2 receptor, ADX-106772, being developed for the treatment of opioid use disorder (OUD).
Read More
Drug capsule spilling onto brain
Substance Use & Poisoning

Adamis announces NIAAA grant to support development of bifunctional molecules for alcohol use disorder

June 27, 2023
Adamis Pharmaceuticals Corp.’s wholly owned subsidiary DMK Pharmaceuticals Corp. has been awarded a grant from the National Institute on Alcohol Abuse and Alcoholism (NIAAA) of the National Institutes of Health (NIH) to support the development of a novel bifunctional small molecule for the treatment of alcohol use disorder.
Read More
Man sitting on bed holding head
Neurology/Psychiatric

Psilera nominates non-hallucinogenic psilocybin derivative as lead clinical candidate

May 26, 2023
Psilera Inc. has selected a novel, non-hallucinogenic psilocybin derivative, PSIL-006...
Read More
Previous 1 2 3 4 5 6 7 8 9 10 11 … 119 120 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 18, 2026.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 16, 2026
  • Red blood cells, DNA

    For clonal hematopoiesis, epigenetics can be in driver’s seat

    BioWorld Science
    Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
  • Brain with puzzle piece removed

    Gene replacement rescues autism-related phenotypes in mice

    BioWorld Science
    Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...
  • Illustration of amyloid plaques in Alzheimer's disease

    Elixiron’s enrupatinib shows upbeat interim phase II AD results

    BioWorld
    Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing